Agios’ Mitapivat Shows Improvement In Regularly Transfused PKD Patients
Results Follow ACTIVATE Study Data In December
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.
You may also be interested in...
The company hopes to grow the current diagnostic rate from 30% to 70% over two to five years. “Optimal reimbursement” for mitapivat will likely take a year, with Medicare/Medicaid lagging.
Nine prominent drug candidates are awaiting an FDA approval decision in the next few months. With the help of Biomedtracker's Early 2022 Outlook Report, we take a look at the potential launches likely to shake up the market from HIV to wet AMD.
The preclinical start-up is identifying allosteric binders that can inhibit or activate metabolic proteins. Atavistik will focus on genetically defined diseases then test its candidates in broader populations.